1-(3,4-二氯苄基)-4-哌啶酮 | 220772-52-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(3,4-二氯苄基)-4-哌啶酮
• 英文名称: 1-(3,4-dichlorobenzyl)-4-piperidone
• 英文别名: 1-(3,4-Dichloro-benzyl)-piperidin-4-one；1-(3,4-dichlorobenzyl)-4-piperidinone；1-(3,4-Dichlorobenzyl)piperidin-4-one；1-[(3,4-dichlorophenyl)methyl]piperidin-4-one
• CAS: 220772-52-1
• 化学式: C₁₂H₁₃Cl₂NO
• mdl: MFCD10695077
• 分子量: 258.147
• InChiKey: LOOMBOWXPYTHIA-UHFFFAOYSA-N

物化性质

• 沸点：
  367.9±37.0 °C(Predicted)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3,4-二氯苄基)-4-哌啶酮 在 platinum(IV) oxide 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 4-哌啶乙酸,1-[(3,4-二氯苯基)甲基]-,乙基酯
  参考文献：
  名称：

  Design and synthesis of novel CCR3 antagonists

  摘要：

  As part of our investigation into the development of potent CCR3 antagonists, a series of piperidine analogues was designed and prepared. Exploration of the piperidine core examined both the basicity and the location of a nitrogen, as well as conformational variants. The bicyclo-piperidine 24c was found to be the most potent inhibitor of CCR3 with an IC50 of 0.0082 muM in the binding assay and 0.0024 muM in the chemotaxis assay. (C) 2003 Published by Elsevier Ltd.

  DOI：

  10.1016/s0960-894x(03)00748-0
• 作为产物：
  描述：

  4-氧代哌啶酮盐酸盐 、 3,4-二氯氯苄 在 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 20.0h， 生成 1-(3,4-二氯苄基)-4-哌啶酮
  参考文献：
  名称：

  Substituted piperidine compounds useful as modulators of chemokine receptor activity

  摘要：

  这项发明提供了式（I）中R1、R2、R3、R6、Z、Q、m、n、X1、X2、X3、X4和T的化合物，其制备方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是用于治疗与趋化因子受体相关的疾病和症状。

  公开号：

  US06903085B1

文献信息

• Cyclic amine derivatives-CCR-3 receptor antagonists
  申请人：Syntex (U.S.A.) LLC

  公开号：US06339087B1

  公开（公告）日：2002-01-15

  This invention relates to certain cyclic amine derivatives of Formula (I) that are CCR-3 receptor antagonist, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

  这项发明涉及某些符合以下式（I）的环胺衍生物，它们是CCR-3受体拮抗剂，包含它们的药物组合物，以及它们的使用方法和制备这些化合物的方法。
• Cyclic amine derivatives- CCR-3 receptor antagonists
  申请人：Syntex (U.S.A.) LLC

  公开号：US06323223B1

  公开（公告）日：2001-11-27

  This invention relates to certain cyclic amine derivatives of Formula (I) that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

  这项发明涉及公式(I)的某些环氨基衍生物，它们是CCR-3受体拮抗剂，包含它们的药物组合物，其使用方法以及这些化合物的制备方法。
• Allosteric Modulation of the Adenosine A₁ Receptor. Synthesis and Biological Evaluation of Novel 2-Amino-3-benzoylthiophenes as Allosteric Enhancers of Agonist Binding
  作者：Pieter A. M. van der Klein、Angeliki P. Kourounakis、Ad P. IJzerman

  DOI：10.1021/jm991051d

  日期：1999.9.1

  Novel allosteric enhancers of agonist binding to the rat adenosine Al receptor are described. The lead compound for the new series was PD 81,723 ((2-amino-4,5-dimethyl-3-thienyl)[3(trifluoromethyl)phenyl]methanone), a compound previously reported by Bruns and co-workers (Mol. Pharmacol. 1990, 38, 950-958). The 4,5-dimethyl group and the benzoyl moiety were targets for further modifications, leading to series of 4,5-dialkyl (12a-g), of tetrahydrobenzo (12h-u), and of tetrahydropyridine (13a-g) derivatives. A number of compounds, in particular 12b, 12e, 12j, 12n, and 12u, proved superior to PD 81,723, Their EC50 values for enhancing the binding of the adenosine Al receptor agonist N-6-cyclopentyladenosine to the receptor were lower, and/or their antagonistic activity on the adenosine Al receptor was shown to be diminished.
• The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: Antagonists versus agonists
  作者：Pauline C. Ting、Shelby P. Umland、Robert Aslanian、Jianhua Cao、Charles G. Garlisi、Ying Huang、James Jakway、Zhidan Liu、Himanshu Shah、Fang Tian、Yuntao Wan、Neng-Yang Shih

  DOI：10.1016/j.bmcl.2005.04.054

  日期：2005.6

  Structure-activity relationship study of bipiperidine amide I has identified the reverse bipiperidine amide 4a as a CC chemokine-3 (CCR3) receptor antagonist. Optimization of the structure-activity relationship of compound 4a has resulted in the identification of a CCR3 antagonist 4i as well as a CCR3 agonist 13. (c) 2005 Elsevier Ltd. All rights reserved.
• CCR-3 receptor antagonists
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0903349B1

  公开（公告）日：2006-01-04